Table 4.

Adverse events suspected to be treatment related in ≥15% of patients (safety set).

AEs	Buparlisib daily dose (+imatinib 400 mg)										All patients
	40 mg n = 4, n (%)		50 mg n = 4, n (%)		70 mg n = 3, n (%)		80 mg n = 43, n (%)		100 mg n = 6, n (%)		n = 60, n (%)
	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4
Total	4 (100)	1 (25.0)	4 (100)	1 (25.0)	3 (100)	1 (33.3)	42 (97.7)	20 (46.5)	6 (100)	4 (66.7)	59 (98.3)	27 (45.0)
Nausea	0	0	3 (75.0)	0	1 (33.3)	0	22 (51.2)	1 (2.3)	3 (50.0)	0	29 (48.3)	1 (1.7)
Fatigue	1 (25.0)	0	0	0	2 (66.7)	0	17 (39.5)	0	3 (50.0)	0	23 (38.3)	0
Diarrhoea	2 (50.0)	0	0	0	1 (33.3)	0	16 (37.2)	1 (2.3)	2 (33.3)	1 (16.7)	21 (35.0)	2 (3.3)
Hyperglycaemia	0	0	1 (25.0)	0	1 (33.3)	0	9 (20.9)	0	5 (83.3)	1 (16.7)	16 (26.7)	1 (1.7)
Rash	0	0	0	0	1 (33.3)	0	11 (25.6)	3 (7.0)	1 (16.7)	1 (16.7)	13 (21.7)	4 (6.7)
Decreased appetite	1 (25.0)	1 (25.0)	1 (25.0)	0	0	0	6 (14.0)	1 (2.3)	2 (33.3)	0	10 (16.7)	2 (3.3)

AE adverse event.